Investor Relations

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV).  Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.

We are also developing a pipeline of oncology, anti-viral and metabolic therapeutics that leverage our expertise in RNA interference (RNAi) therapeutics and leading Lipid Nanoparticle (LNP) technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body’s own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell.

With a proven management team and scientific leadership in antiviral and RNAi drug discovery and development, we are developing a robust pipeline of products with the goal of optimizing value for our shareholders and partners, and to serve patients worldwide.

View all »   RSSRecent Releases

Apr 22, 2015
Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results

Apr 22, 2015
Tekmira and Collaborators Publish Positive Preclinical Ebola Survival Data in Nature Journal


View all »Events & Presentations

May 6, 2015 at 1:30 PM PT
Tekmira Provides Corporate Update and Announces First Quarter Results

Mar 27, 2015
7th International Symposium on Filoviruses